客户的评价

我们的客户

以及客户对我们的评价

valo health 88945793
“Catenion is an outstanding partner. They deeply understand the needs of a client, work closely with the utmost professionalism and focus on key outcomes, with unwavering focus. Their insights are top notch across the board with true scientific rigor.”
David Berry
Valo Health / Flagship Pioneering
CEO / General Partner
Mkgaa768x432
“When dealing with strategic topics related to R&D, Catenion is my partner of choice. They bring unique perspectives and frameworks, and their deep rooting in science and technology clearly differentiates them from other consulting firms that I know.”
Dr. Stefan Oschmann
Merck KGaA
CEO
Logo Bayer
“One of the toughest decisions I had to take in my role as CEO of Bayer Pharma was to refocus our Discovery activities after the market withdrawal of Lipobay. Using their proprietary tools, benchmarks and a tough, fact–based approach, Catenion guided the Discovery management team through a difficult process of prioritisation of therapeutic areas and projects and provided crucial support for the decision making of the Bayer Corporate Board.”
Dr. Wolfgang Plischke
Bayer Pharma
CEO
Endocyte NovartisCo
“Catenion was able to identify and address the fundamental questions across every aspect of the value chain for each of the programs we assessed. Their insight into the science, regulatory landscape, manufacturing challenges, competitive dynamics, and commercial potential provided an objective understanding of the risks and opportunities.”
Endocyte
CEO
download 1
“We have successfully worked with Catenion on various strategic- and portfolio related- topics. They really go deep into the science and are able to translate insights into effective strategies. They are fully at home in the world of US biotech and have an extensive network in Europe and Japan.”
Jon P. Stonehouse
Biocryst Pharmaceuticals Inc.
President and CEO
TevaPharm.svg
“Teva Pharmaceuticals asked Catenion to do a comprehensive assessment of our specialty pipeline supporting the executive team to define the future specialty strategy. Catenion was not shy of asking tough questions related to our R&D programs and portfolio selection. Our R&D organization highly appreciated their collaborative approach, scientific depth and independent mindset. Catenion convinced our R&D and executive teams, as well as the Board with independent recommendations based on real analytical depth. Crucially, their understanding of the organizational dynamics of decision-making in large organizations resulted in actionable results out of this project. I would recommend them to anybody who has challenging R&D strategy-related topics and requires an in-depth analysis of pipeline assets.”
Dr. Sven Dethlefs
Teva Pharmaceuticals
Executive Vice President, North America Commercial
Israel Innovation Authority logo
“In a year-long effort, Catenion helped us draft a long-term strategy and implementation plan, which has now become official policy of the IIA; they were crucial to the success of our strategy project and I strongly recommend them to any policy-makers intent on strengthening their local biomedical innovation systems.”
Anya Eldan
Israel Innovation Authority
VP, Head of Start-up Division
Verastem Oncology official company logo
“We found Catenion’s approach to be scientifically rigorous, and unbiased. Their team was world class, and provided invaluable insight to our management team.”
Robert Forrester
Verastem Inc.
President and CEO
index
“I would wholeheartedly recommend Catenion to academic and governmental decision-makers wishing to get their universities and hospitals on the global map of biomedical innovation.”
Dr. Giora Yaron
Tel Aviv University
Chairman
1603712490Fresenius Facebook Logo
“I very much enjoy working with Catenion who combine a deep understanding of biomedical innovation and scientific understanding with strategic acumen and organizational savvy and I strongly recommend them to anybody with challenging strategic questions at the interface between academia and industry.”
Dr. Olaf Schermeier
Global Research & Development, Fresenius Medical Care
CEO
Sumitomo Dainippon Pharma.svg
“Catenion have repeatedly supported our globalization strategy with practical advice – their in-depth understanding of the bio-pharmaceutical industry, its players and the R&D dynamic have been extremely helpful for us. We also appreciate their strong presence in Japan and understanding of Japanese culture.”
Makoto Hara
Sumitomo Dainippon Pharmaceuticals Co., Ltd.
Executive Vice President
images
“Catenion supported us in a very critical situation with a key late stage development project. Due to their pragmatic, critical and entrepreneurial approach, they largely contributed to the success of the crisis management team. My very positive experiences with the Catenion consultants during project/portfolio reviews have now also been confirmed at a tactical and operational level within a global project team.”
Dr. Oliver Maria Wilbert
Merck Serono SA
Senior Director Immunotherapies, Portfolio Development
Grunenthal LightGreen CMYK 300dpi
“We have been working several times with Catenion and have always been extremely satisfied by the quality of the contribution which helped us to find robust and smart answers to the questions we worked on together. Catenion has been very instrumental by forcing the organization to question the current dogma. Catenion clearly stands out among the small and big consulting companies I have worked with.”
Prof. Dr. Eric-Paul Pâques
Grünenthal GmbH
CEO
ottobock blue og fallback 16 9 teaser onecolumn retina
“Ottobock HealthCare is the world market leader in prosthetics. Our major growth driver is the development and marketing of new and innovative products. With the intention to optimize our pipeline management we decided to implement portfolio management in our Prosthetics Business Unit. This has established great transparency regarding risk, commercial potential and strategic fit of R&D projects and marketed products. On that basis we are able to truly measure where we stand in R&D and in commercial terms versus our ambitious goals and are able to make timely adjustments, where required. Simultaneously portfolio management also supports our strategic planning of the development pipeline. During this entire journey, Catenion proved to be a true partner on strategic and operative levels for us and our teams.”
Dr. Helmut Pfuhl / Dr. Hans Dietl
Otto Bock HealthCare GmbH
Executive Vice President / Chief Technology Officer
1200px Drägerwerk.svg
“With their systematic review of the key drivers of innovation and risk, Catenion has helped us focus our early stage medical devices and technology portfolios on the most promising assets. Their approach of on–the–job training our portfolio managers in the methodology and staying in the background led to great acceptance in the organization. As a result, we have decided to implement their approach. I have worked with Catenion for many years and in various roles and have always highly valued their contribution.”
Dr. Ulrich Thibaut
Drägerwerk AG
Member of the Board of Management (CTO)
index
“Apart from their strong analytics, what I particularly appreciated was the pragmatic approach of the Catenion team. Without eschewing clarity and conflict where necessary, they involved the organization with a constructive, participatory spirit, thus turning initial apprehension into positive energy for implementation that we could harness for the change the company needed.”
Rob Koremans
Aventis Sanofi
Senior Vice President / CEO Generics Europe
2560px Boehringer Ingelheim Logo.svg
“Over the years, I have come to know Catenion as independent thinkers who use their insights and methodological sophistication to come up with creative solutions that work.”
Bert Tjeenk Willink
Boehringer Ingelheim
Member of the Board of Managing Directors, Head of Corporate Board Division Marketing and Sales
download 1
“Catenion has supported us on a number of portfolio and strategy related projects at a critical time in the company’s history as we focus our R&D efforts on creating future value. They bring very disciplined and cutting–edge methods and processes, but most importantly they understand our needs and requirements as a fast–paced biotech company. I really value their independent point of view, which has been instrumental in challenging and guiding our senior team in coming up with a winning portfolio strategy.”
David S. McCullough
BioCryst Pharmaceuticals, Inc.
Vice President, Strategic Planning, Commercialization & Corporate Development
1200px Lundbeck Logo.svg
“We have successfully used Catenion for R&D portfolio management and strategy support. Catenion’s in–depth understanding of pharmaceutical R&D and their sharp analytical approach clearly differentiates them. Our collaboration has been efficient, valuable and constructive.”
Dr. Claus Braestrup
H. Lundbeck A/S
President and CEO
2000px GlaxoSmithKline Logo.svg
“What I particularly appreciated in working with Catenion on the Personalised Medicine strategy for GSK is the rare combination of an in–depth understanding of the science (biomarkers, pharmacology, diagnostics, clinical trial designs, modelling tools..), the R&D processes, their very thorough strategic vision for R&D as well as the quality of their well articulated risk assessment tools both for R&D and commercial purposes. Through them I was able to develop a better vision of the key opportunities but also the real challenges of a Personalised Medicine Strategy. Their approach is robust and well qualified – it embeds the right balance of inspiration and pragmatism associated with a high level of discipline in collecting data and facts. Last but not least their sound assessment of organisations contributes to their remarkable sense of how to achieve the transformational benefit of new R&D approaches.”
Dr. Dominique Limet
Glaxo SmithKline
SVP & Head of Personalised Medicine Strategy
universidad de navarra vector logo
“Catenion supported us in evaluating our portfolio as a basis for making decisions on future strategy and focus of CIMA. They brought the right mix of analytical rigor and pragmatism necessary to go through a very large and heterogeneous group of projects. Their consultants had the cultural sensitivity required to successfully operate in an academic environment. Having a background in ‘Big Pharma’, I greatly enjoyed the challenge of translating tools from that area to help us improve, but at the same time keeping the creative spark alive that is the lifeblood of a translational research institute like CIMA.”
Jesús M. Hernández
University of Navarra
COO, CIMA
images
“Catenion’s approach to assessing risk and value on both a project and portfolio level goes way beyond what is usually discussed in senior executive teams. It has allowed us to create a very solid foundation of information, which is the key to understanding the portfolio. Their process and independent points of view have greatly helped our Executive Management Board take difficult decisions during a challenging post–merger review of the portfolio, and going forward we have decided to implement their approach as the framework for us to manage our portfolio.”
Vincent Aurentz
Merck Serono SA
Executive VP, Business Development & Portfolio Management
Hoffmann-La_Roche_logo.svg
“I tremendously enjoyed working with Catenion. They are fully at home in pharmaceutical Discovery and bring a highly unusual combination of a rigorous analytical mind–set with a pragmatic understanding of R&D strategy and organisational mechanics.”
Dr. Gianni Gromo
F. Hoffmann–La Roche AG
Global Head Metabolic & Vascular Disease Area
logo giuliani
“I have worked with Catenion on several occasions — from an in–depth assessment of our ethical pipeline, to health–economic analyses, to a customised training for my executive team by The Catenion Academy. The Catenion team always focused on our specific needs as a family–owned business while providing the perspective of large pharmaceutical corporations. Their insights had great impact on our internal discussions and development.”
M. Germano Giuliani
Giuliani S.p.A.
President & CEO
medivir big
“We worked with Catenion to provide training and support for a new Portfolio Review System. They introduced us to their Risky Business Game which enabled the whole company to engage in a full day of intensive simulations that mirrored the real life decisions that our company has to take in managing its R&D portfolio. This proved to be an exceptional learning experience for our staff but also one which everyone enjoyed immensely. The Catenion team were extremely professional, knowledgeable and helpful in both the preparation and the execution of this very important training event.”
Ron Long
Medivir AB
CEO
Note: Affiliations at the time of the collaboration with Catenion.